This firm currently holds 327.21
M in liabilities with Debt to Equity (D/E) ratio of 49.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PTC Therapeutics dividends can provide a clue to current valuation of the stock. The firm is not expected to issue dividends this year as it trying to preserve or re-invest any of the funds available for distribution to stakeholders. Lets now take a look at PTC Therapeutics Market Capitalization. Based on recorded statements the market capitalization of PTC Therapeutics is about 3.02
B. This is 76.66% lower than that of the Healthcare sector, and 36.3% lower than that of
Biotechnology industry, The Market Capitalization for all stocks is 84.13% higher than the firm.
PTC Therapeutics owns negative utilization of current and long term assets of -7.4 %, securing only $0.07 for each dollar of current and long term assets held by the company. Unproductive assets utilization implies the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking assets utilization of PTC Therapeutics shows how inefficient it operates for each dollar spent on its current and long term assets. The latest increase in of PTC Therapeutics short term price appreciation may encourage investors to take a closer look at the company as it closed today at a share price of
47.67 on
553290.000 in trading volume. The company directors and management have been quite successful with maneuvering the fund at opportune times to take advantage of all market conditions in
November. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.14. The current volatility is consistent with the ongoing market swings in
November 2019 as well as with PTC Therapeutics unsystematic, company specific events. PTC Therapeutics reports 4.0 z score. PTC Therapeutics is selling at 48.38. That is 0.75 percent increase. Today lowest is 47.67. PTC Therapeutics Operating Margin is decreasing over the last 5 years. Also, PTC Therapeutics Net Income Common Stock USD is comparatively stable at the moment.
| 2018 | 2019 (projected) |
Revenues USD | 42.28 M | 49.59 M | Revenues | 264.73 M | 296.86 M |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey. PTC Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 511 people.
Revenues USDRevenuesOn the whole, we believe that at this point PTC Therapeutics is not too volatile with
low chance of bankruptcy within the next 2 years. Our overall buy-sell advice on the firm is
Buy.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of PTC Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com